Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Inge Hermens

2PUBLICATIONS

35CO-AUTHORS

Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (2)

Sort by Publication Date:

|Apr 12, 2023

Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody-Drug Conjugate.

Patrick G Groothuis, Daniëlle C H Jacobs, Inge A T Hermens

|Apr 02, 2021

Clinically applicable CD34<sup>+</sup>-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses.

Jesper van Eck van der Sluijs, Diede van Ens, Soley Thordardottir

Pageof 1

Frequent Collaborators

1 joint publications

Patrick G Groothuis

1 joint publications

Daniëlle C H Jacobs

1 joint publications

Désirée Damming

1 joint publications

Kim Berentsen

1 joint publications

Ellen Mattaar-Hepp

1 joint publications

Marloes E M Stokman

1 joint publications

Tinie van Boekel

1 joint publications

Myrthe Rouwette

1 joint publications

Monique A J van der Vleuten

1 joint publications

Aloys Sesink

Frequent Collaborators

1 joint publications

Patrick G Groothuis

1 joint publications

Daniëlle C H Jacobs

1 joint publications

Désirée Damming

1 joint publications

Kim Berentsen

Top Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on : Mar 08, 2018

Tractable <em>In Vivo</em> Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable <em>In Vivo</em> Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on : Aug 01, 2025

See more related videos

Top Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on : Mar 08, 2018

Tractable <em>In Vivo</em> Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable <em>In Vivo</em> Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on : Aug 01, 2025

See more related videos